Recombinant Factor VIII Concentrates

 

 Buy Article Permissions and Reprints

ABSTRACT

The development and introduction of recombinant factor VIII (rFVIII) concentrates nearly 20 years ago represented a major advance in the treatment of hemophilia A patients. Currently, first-, second- and third-generation rFVIII products are commercially available. Whereas first-generation rFVIII concentrates are stabilized with human albumin, second-generation rFVIII products contain sucrose instead of albumin in the final formulation. Finally, third-generation rFVIII products are manufactured without additional human or animal plasma proteins. The use of rFVIII concentrates has greatly improved the safety of replacement therapy in hemophilia A and virtually abolished the risk of blood-borne pathogen transmission. The remaining and most challenging aspect of hemophilia A management has now become the development of FVIII inhibitors. In this article we review the current knowledge on the commercially available rFVIII concentrates, analyzing their main characteristics. Moreover, results of the literature on their clinical hemostatic efficacy and safety are summarized.

REFERENCES

• 1 Kasper C K. Concentrate safety and efficacy.  Haemophilia. 2002;  8(T3) 161-165
  CrossrefPubMedGoogle Scholar
• 2 Mannucci P M, Tuddenham E G. The hemophilias—from royal genes to gene therapy.  N Engl J Med. 2001;  344(23) 1773-1779
  CrossrefPubMedGoogle Scholar
• 3 Leissinger C A. Prophylaxis in haemophilia patients with inhibitors.  Haemophilia. 2006;  12(Suppl 6) 67-72 discussion 72-73
  CrossrefPubMedGoogle Scholar
• 4 Toole J J, Knopf J L, Wozney J M et al.. Molecular cloning of a cDNA encoding human antihaemophilic factor.  Nature. 1984;  312(5992) 342-347
  CrossrefPubMedGoogle Scholar
• 5 Pipe S W. Recombinant clotting factors.  Thromb Haemost. 2008;  99(5) 840-850
  PubMedGoogle Scholar
• 6 Josephson C D, Abshire T. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?.  Clin Adv Hematol Oncol. 2004;  2(7) 441-446
  PubMedGoogle Scholar
• 7 Lusher J M, Scharrer I. Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.  Int J Hematol. 2009;  90(4) 446-454
  CrossrefPubMedGoogle Scholar
• 8 Musso R. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.  Drugs Today (Barc). 2008;  44(10) 735-750
  CrossrefPubMedGoogle Scholar
• 9 Lippi G, Franchini M, Favaloro E J. One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin.  Blood Coagul Fibrinolysis. 2009;  20 1-3
  CrossrefPubMedGoogle Scholar
• 10 Ingerslev J, Jankowski M A, Weston S B, Charles L A. ReFacto Field Study Participants . Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr factor VIII:C activity in hemophilic plasma using one-stage clotting assays.  J Thromb Haemost. 2004;  2(4) 623-628
  CrossrefPubMedGoogle Scholar
• 11 Pipe S. Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A.  Biologics. 2009;  3 117-125
  PubMedGoogle Scholar
• 12 Dargaud Y, Negrier C. Haemophilia therapies.  Expert Opin Biol Ther. 2007;  7(5) 651-663
  CrossrefPubMedGoogle Scholar
• 13 Farrugia A. Evolving perspectives in product safety for haemophilia.  Haemophilia. 2002;  8(3) 236-243
  CrossrefPubMedGoogle Scholar
• 14 Schimpf K. On the way to virus-safe blood coagulation factor concentrates.  Semin Thromb Hemost. 2002;  28(suppl 1) 15-24
  PubMedGoogle Scholar
• 15 Tagliaferri A, Rivolta G F, Iorio A et al.. Mortality and causes of death in Italian persons with haemophilia, 1990–2007.  Haemophilia. 2010;  , February 9 (Epub ahead of print)
  PubMedGoogle Scholar
• 16 Bray G L, Gomperts E D, Courter S The Recombinate Study Group et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A.  Blood. 1994;  83(9) 2428-2435
  PubMedGoogle Scholar
• 17 White II G C, Courter S, Bray G L, Lee M, Gomperts E D. The Recombinate Previously Treated Patient Study Group . A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A.  Thromb Haemost. 1997;  77(4) 660-667
  PubMedGoogle Scholar
• 18 Abshire T C, Brackmann H H, Scharrer I et al.. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy—International Kogenate-FS Study Group.  Thromb Haemost. 2000;  83(6) 811-816
  PubMedGoogle Scholar
• 19 Lusher J M, Lee C A, Kessler C M, Bedrosian C L. ReFacto Phase 3 Study Group . The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.  Haemophilia. 2003;  9(1) 38-49
  PubMedGoogle Scholar
• 20 Tarantino M D, Collins P W, Hay C R RAHF-PFM Clinical Study Group et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.  Haemophilia. 2004;  10(5) 428-437
  CrossrefPubMedGoogle Scholar
• 21 Lusher J M. First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development.  Semin Thromb Hemost. 2002;  28(3) 273-276
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Kreuz W, Gill J C, Rothschild C International Kogenate-FS Study Group et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.  Thromb Haemost. 2005;  93(3) 457-467
  PubMedGoogle Scholar
• 23 Musso R, Santagostino E, Faradji A KOGENATE Bayer European PMS Study Group et al. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.  Thromb Haemost. 2008;  99(1) 52-58
  PubMedGoogle Scholar
• 24 Shi J, Zhao Y, Wu J, Sun J, Wang L, Yang R. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China.  Haemophilia. 2007;  13(4) 351-356
  CrossrefPubMedGoogle Scholar
• 25 Shapiro A, Gruppo R, Pabinger I et al.. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A.  Expert Opin Biol Ther. 2009;  9(3) 273-283
  CrossrefPubMedGoogle Scholar
• 26 Lusher J M. Is the incidence and prevalence of inhibitors greater with recombinant products? No.  J Thromb Haemost. 2004;  2(6) 863-865
  CrossrefPubMedGoogle Scholar
• 27 Aledort L M. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes.  J Thromb Haemost. 2004;  2(6) 861-862
  CrossrefPubMedGoogle Scholar
• 28 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review.  Haemophilia. 2003;  9(4) 418-435
  CrossrefPubMedGoogle Scholar
• 29 Gouw S C, van den Berg H M. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.  Semin Thromb Hemost. 2009;  35(8) 723-734
  Article in Thieme ConnectPubMedGoogle Scholar
• 30 Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.  Thromb Haemost. 1996;  76(5) 749-754
  PubMedGoogle Scholar
• 31 Bajwa N, Enriquez M M, Gorina E, Lemm G. Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII.  Haemophilia. 2009;  15(2) 597-600
  CrossrefPubMedGoogle Scholar
• 32 Scharrer I, Ehrlich H J. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.  Haemophilia. 2001;  7 346-348
  CrossrefPubMedGoogle Scholar
• 33 Goudemand J, Rothschild C, Demiguel V FVIII-LFB and Recombinant FVIII study groups et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.  Blood. 2006;  107(1) 46-51
  CrossrefPubMedGoogle Scholar
• 34 Chalmers E A, Brown S A, Keeling D Paediatric Working Party of UKHCDO et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.  Haemophilia. 2007;  13(2) 149-155
  CrossrefPubMedGoogle Scholar
• 35 Gouw S C, van der Bom J G, Auerswald G, Ettinghausen C E, Tedgård U, van den Berg H M. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.  Blood. 2007;  109(11) 4693-4697
  CrossrefPubMedGoogle Scholar
• 36 Ettingshausen C E, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.  Haemophilia. 2006;  12(Suppl 6) 102-106
  PubMedGoogle Scholar
• 37 DiMichele D M, Hoots W K, Pipe S W, Rivard G E, Santagostino E. International workshop on immune tolerance induction: consensus recommendations.  Haemophilia. 2007;  13(Suppl 1) 1-22
  PubMedGoogle Scholar
• 38 Santagostino E, Mannucci P M, Bianchi Bonomi A. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy.  Haemophilia. 2000;  6(1) 1-10
  PubMedGoogle Scholar
• 39 United Kingdom Haemophilia Centre Doctors' Organisation . Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.  Haemophilia. 2003;  9(1) 1-23
  PubMedGoogle Scholar
• 40 Batlle J, Villar A, Liras A et al.. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain.  Blood Coagul Fibrinolysis. 2008;  19(5) 333-340
  CrossrefPubMedGoogle Scholar
• 41 Di Minno G, Cerbone A M, Coppola A et al.. Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue.  Haemophilia. 2010;  16(Suppl 1) 2-6
  CrossrefPubMedGoogle Scholar
• 42 Chuah M K, Collen D, VandenDriessche T. Clinical gene transfer studies for hemophilia A.  Semin Thromb Hemost. 2004;  30(2) 249-256
  Article in Thieme ConnectPubMedGoogle Scholar
• 43 Ragni M V. Hemophilia gene transfer: comparison with conventional protein replacement therapy.  Semin Thromb Hemost. 2004;  30(2) 239-247
  Article in Thieme ConnectPubMedGoogle Scholar
• 44 Viiala N O, Larsen S R, Rasko J E. Gene therapy for hemophilia: clinical trials and technical tribulations.  Semin Thromb Hemost. 2009;  35(1) 81-92
  Article in Thieme ConnectPubMedGoogle Scholar
• 45 Lippi G, Franchini M, Saenko E L. Gene therapy for hemophilia A. Friend or foe?.  Blood Coagul Fibrinolysis. 2009;  20(6) 395-399
  CrossrefPubMedGoogle Scholar

Massimo FranchiniM.D. 

Servizio di Immunoematologia e Trasfusione

Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

Email: massimo.franchini@azosp.vr.it